title: [Analysis of outocome of pirarubicin-based combination chemotherapy regimen in the treatment of newly diagnosed acute myeloid leukemia-a prospective, open, randomized and multicenter clinical trial].
abstract: OBJECTIVE
  To compare the effectiveness and side effects of two chemotherapy regimens [pirarubicin + cytarabine (TA) and daunorubicin + cytarabine (DA)] in patients with acute myeloid leukemia (AML).
  
  
  METHODS
  From Oct 2006 to Jul 2009, there were 207 newly diagnosed AML patients randomized into DA or TA group from 72 centers all over the country. The aim of this clinical trial is to observe and evaluate complete remission rate (CR), total remission rate (TRR), and side effect after one or two circles of therapy.
  
  
  RESULTS
  In 198 evaluable patients, 126 cases in TA group and 72 in DA group were evalvable, with a ratio of 1.75:1. CR was 69.8% and TRR (CR + PR) was 81.8% in TA group and 63.9%, 80.9% in DA group, correspondingly (P > 0.05). For patients with subtype M(2), CR (77.1%) in TA group was higher than that in DA (60%). There was no difference in side effect between the two groups.
  
  
  CONCLUSIONS
  There is no difference of the effect between TA and DA chemotherapy for newly diagnosed AML patients. But for subtype M(2), TA is more efficacy. And there is no difference in side effect between the two regimens.
authors.affiliation: Shanghai Institute of Hematology, Shanghai Jiaotong University Medical School Ruijin Hospital, Shanghai 200025, China.
authors.forename: Yan-Yan
authors.initials: YY
authors.lastname: Wang
authors.forename: Xiao-Mei
authors.initials: XM
authors.lastname: Sheng
authors.forename: Rong-Yan
authors.initials: RY
authors.lastname: Zhang
authors.forename: Xiao-Nan
authors.initials: XN
authors.lastname: Guo
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.forename: Jin-Lin
authors.initials: JL
authors.lastname: Zhang
authors.forename: Jun-Min
authors.initials: JM
authors.lastname: Li
authors.forename: Zhi-Xiang
authors.initials: ZX
authors.lastname: Shen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D011446:Prospective Studies
chemical_list: D003561:Cytarabine; D003630:Daunorubicin